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Aggressive behavior is frequently reported in patients with schizophrenia, and its
prevalence is estimated to be 2 to 10 times that of the general population.
1,2 The
causes of aggressive behavior in schizophrenia are complex and multifactorial,
but a genetic contribution to aggressive behavior has been demonstrated in twin
and adoption studies in community sample.
3-5 There is a large body of evidence to
suggest that disturbances of central serotonin (5-HT) functions play an important
role in aggressive behavior.
6
The gene responsible for 5-HT synthesis, the tryptophan hydroxylase (TPH)
gene, is one of the candidate genes associated with aggression. Several separate
lines of biological evidence which suggest its role in modulating serotonergic
function in the brain
7 together with genetic association studies point to the
involvement of TPH1 in aggression or anger-related traits within various
psychiatric conditions.
8,9 The A218C polymorphism in intron 7 is one of the most
widely studied polymorphisms in this gene and could affect the expression of the
TPH1 gene by causing a strong linkage disequilibrium with other functional
polymorphisms in the promoter region.
10 In the previous case-control genetic
study by Nolan, et al.,
11 a marginal association between TPH1 A218C and
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aggressive schizophrenia was found, only in male patients,
in spite of the small sample size.  
Based on the above findings, we investigated whether
the genetic variant of TPH1 A218C is associated with
aggression in schizophrenic patients. To this end, a case-
control phenotypic comparison was carried out, followed
by an investigation of anger-related traits as traits affecting
aggressive behavior in schizophrenic patients. 
Study population
The sample included 61 aggressive schizophrenic patients
(39 men, 22 women) as well as 104 non-aggressive patients
(57 men, 47 women) and 335 healthy volunteers (204
men, 131 women) recruited from the Korean population.
The DSM-IV diagnosed schizophrenic patients were
recruited to the study between 2004 and 2007 from the
inpatients population in Severance hospital, Seoul, and the
Chookryoung Evangelical Mental Hospital, Gyeonggi,
South Korea. Patients with other comorbid major Axis I
psychiatric disorders were not included in this study. The
aggressive patients were selected according to rigorous
criteria for identifying both a current and past history of
aggressive behavior. As described in previous study,
12
patients were included in the aggressive group if they had
significant episodes of violence, resulting in repeated
confinement at least twice per week in the two weeks prior
to study inclusion, and a past history of aggressive beha-
viour defined as a documented history of at least two (and
frequently many more) serious assaults against others.
Non-aggressive patients were selected for the study if they
had no history of significant assaultive or threatening beha-
vior, reported by family members or staff, and if no such
behavior was observed during the interview. All of the
patients were assessed within 2 weeks after admission and
underwent a psychiatric interview conducted by two inde-
pendent clinicians, based on all available clinical infor-
mation, examination of case records, and information
provided by relatives and mental health professionals.
Patients were assessed by the Modified Over Aggression
Scale (MOAS)
13 for aggressive behavior. We could obtain
the data for anger-related traits by the State-Trait Anger
Expression Inventory (STAXI)
14 in 45 aggressive patients
and 84 non-aggressive patients. Of patients, 52 patients in
the aggressive group and 82 patients in the non-aggressive
group were taking neuroleptics at the time of the study.
When the doses of neuroleptics were converted into chlor-
promazine equivalent doses,
15 there was no significant dif-
ference in the dose of neuroleptics between the aggressive
and non-aggressive patients. A subgroup consisting of
about 30% of the patients within the schizophrenia sample
(13 aggressive patients, 32 non-aggressive patients) also
completed the assessment of symptoms using the Positive
and Negative Syndrome Scale (PANSS) as part of another
ongoing study by our group. There was no significant
difference between the patients who completed PANSS
and those who did not, in terms of age, MOAS or illness
variables (onset, duration, hospitalisation and dose of
neuroleptics) (data available on request). The exclusion
criteria were a history of neurological disorders, substance
abuse in the previous 3 months and an estimated intelligence
quotient (IQ) of less than 70. 
Healthy unrelated Korean volunteers with a mean age of
24.5 years (SD 5.7, range 19-57) were recruited from the
residents of Seoul by advertisement. They had no reported
current or past history of psychiatric disorders, including
significant violent episodes. The Institutional Review
Boards of both Severance Hospital and Chookryoung
Evangelical Mental Hospital approved the study, and
written informed consent was obtained from all partici-
pants or their legal guardians after the nature of the study
was fully explained to them.
State-trait anger expression inventory
The STAXI
14 is a 44-item self-report questionnaire that is
divided into seven scales. It measures the current intensity
of anger (State anger) and disposition toward anger as a
personality trait (Trait anger) using two subscales that
measure the subject’s general disposition toward angry
feelings (Angry temperament) and the tendency to express
anger when criticized (Angry reaction). The other scales
measure the frequency with which provoked anger is
suppressed (Anger-in), the frequency of the expression of
anger toward other people or objects (Anger-out), and the
frequency at which the expression of anger is controlled
(Anger control). The Korean version of the STAXI was
used in this study.
16 The STAXI has demonstrated satisfac-
tory reliability in schizophrenic patients with Cronbach’s α
= 0.82-0.85.
17
Genotyping 
Genotyping was performed blind to history of aggressive
behavior. Genomic DNA was extracted from blood leuko-
cytes by using a commercial DNA extraction kit (ABI,
Foster City, CA, USA). The genotyping of TPH polymor-
phism (A218, rs1800532) was carried out using ABI
PRISM SNaPShot Multiplex kit (ABI, Foster City, CA,
USA) according to manufacturer’s recommendation. Brief-
ly, the genomic DNA flanking the SNP for rs1800532 was
amplified by polymerase chain reaction (PCR) with the
primers 5’-CATGTT CCATGCTCTATATGTGT-3’ and
5’-TGTCTGATT TTTTTCAGTGTTACATT-3’. The
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PCR conditions were as follows: 10 minutes at 95˚C for 1
cycle, and 30 cycles on 95˚C for 30s, 55˚C for 1 min, 72˚C
for 1 min followed by 1 cycle of 72˚C for 7 minutes. After
amplification, the PCR products were treated with 1 unit
each of shrimp alkaline phosphatase (Roche) and
exonuclease I (USB Corporation) at 37˚C for 60 minutes
and 72˚C for 15 minutes. One µL of the PCR products was
added to a SNaPshot Multiplex Ready reaction mixture
containing 0.15 pmols of genotyping primer of TPH (5’-
TTAT TAATTGACAACCTATTAGGTG-3’) for primer
extension reaction. The primer extension reaction was
carried out for 25 cycles of 96˚C for 10 seconds, 50˚C for
5 seconds, and 60˚C for 30 seconds. The reaction products
were treated with 1 unit of SAP at 37˚C for 1 hour and
72˚C for 15 minutes to remove excess fluorescent dye
terminators. One µL of the final reaction sample containing
the extension products was added to 9 µL of Hi-Di forma-
mide (ABI, Foster City, CA, USA). The mixture was
incubated at 95˚C for 5 minutes, followed by 5 minutes on
ice and then analyzed by electrophoresis in ABI Prism
3730xl DNA analyzer. Results were analyzed using
GeneScan analysis software (ABI, Foster City, CA, USA).
Deviation from Hardy-Weinberg equilibrium was assessed
as described by Wigginton, et al.
18
Statistical analyses
The differences in the genotype and allele frequencies
between the affected (aggressive patients) and unaffected
individuals (non-aggressive patients or healthy volunteers)
were evaluated using a χ 2 test. To test the interaction
between the genotypes and group (aggressive patients and
non-aggressive patients) on anger-related traits, multiva-
riate analysis of variance (MANOVA) was performed,
followed by univariate analysis. Gender was entered as a
covariate in all analyses to control the possible gender
effect on the genotype.
19 p-values < 0.05 were considered
as significant. All statistical tests were performed using
SPSS version 11.0. 
The demographic and clinical characteristics of the patients
are shown in Table 1. As shown, the aggressive and non-
aggressive patients did not differ in age, age at onset or
educational level. As expected, the aggressive patients had
RESULTS
Table 1.The Epidemiological and Clinical Data of the Schizophrenic Patients 
Characteristics
Aggressive Non-aggressive Analysis
patients (n = 61) patients (n = 104) t df p
Age (yrs) 36.8 (9.4) 39.4 (10.4) 1.55  163 0.124
Age at onset (yrs) 25.1 (6.8) 24.2 (7.0) 0.71  139 0.479
Education (yrs) 12.2 (3.4) 11.9 (3.0) 0.41  120 0.680
Chlorpromazine equivalent doses (mg) 527.7 (394.5) 425.3 (324.1) 1.64  133 0.103
MOAS, total score 19.1 (7.4) 6.2 (8.2) 9.03  133 < 0.001
STAXI, total score 106.7 (20.5) 90.9 (20.3) 4.21  127 < 0.001
Data are mean (SD).
MOAS, modified over aggressionscales; STAXI, state-trait anger expression inventory.
Table 2.Frequency of Genotypes and Alleles for the TPH1A218C Gene in Aggressive Schizophrenic Patients, Non-Aggressive
Schizophrenic Patients and Healthy Volunteers, Stratified by Gender
Genotype Allele
A/A A/C C/C Analysis* A C Analysis*
n % n % n % χ 2
2 pn % n % χ 2
1 p
Aggressive patients (n = 61) 15 25 30 49 16 26 60 49 62 51
Male (n = 39) 8 21 19 49 12 31 35 45 43 55
Female (n = 22)  7 32 11 50 4 18 25 57 19 43
Non-aggressive patients (n = 104) 28 27 49 47 27 26 0.12 0.944 105 50 103 50 0.05 0.820
Male (n = 57) 13 23 30 53 14 25 0.46 0.797 56 49 58 51 0.34 0.562
Female (n = 47)  15 32 19 40 13 28 0.86 0.650 49 52 45 48 0.27 0.607
Healthy controls (n = 335)  66 20 180 54 89 27 0.81  0.668 312 47 358 53 0.28 0.595
Male (n = 204) 43 21 107 53 54 27 0.32 0.854 193 47 215 53 0.16 0.693
Female (n = 131)  23 18 73 56 35 27 2.60 0.272 119 45 143 55 1.96 0.161
*Comparisons of aggressive patients with non-aggressive patients or healthy volunteers. Youl-Ri Kim, et al.
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significantly higher scores in MOAS and STAXI than the
non-aggressive patients. In addition, the positive scale
[24.7 (9.8) vs. 14.5 (8.2); t = 3.7, df = 43, p = 0.001], nega-
tive scale [19.5 (7.0) vs. 13.2 (7.1); t = 2.8, df = 43, p =
0.007], general subscale [48.4 (16.7) vs. 28.3 (12.4); t =
4.5, df = 43, p < 0.001], and total PANSS scores [92.0
(30.8) vs. 56.7 (25.2); t = 4.0, df = 43, p < 0.001] of the
aggressive patients were significantly higher than those of
the non-aggressive patients. 
The genotype and allele frequencies of the variants for
the aggressive and non-aggressive patients with schizo-
phrenia are shown in Table 2, along with those for the
healthy controls. The TPH1 A218C genotype frequencies
in both the healthy controls and schizophrenic patients did
not deviate from Hardy-Weinberg equilibrium. There were
no significant differences in the genotype or allele frequen-
cies between the aggressive patients and controls (non-
aggressive patients or healthy volunteers). When the anal-
ysis was stratified by gender, the genotype and allele fre-
quencies in the aggressive, non-aggressive patients groups
and healthy volunteers were not significantly different. 
A MANOVA was computed for patients with schizo-
phrenia by integrating the seven STAXI subscales as well
as three factors: the genotype, group and gender. We could
not find any effect of genotype on the anger-related traits
or any interaction among the genotype, groups, and gender
(Table 3). In further detailed univariate analysis followed
for genotype effects, there was no effect of genotype on
the STAXI subscales in aggressive or non-aggressive
patients (Table 4).
In the present study, tests of association with a case-control
phenotypic comparison and continuous outcome for anger-
related traits revealed no evidence of an association between
the TPH1 A218C gene and aggression in schizophrenic
patients. 
To the best of our knowledge, this is the first study to
systematically investigate the association between the
tryptophan hydroxylase gene and aggressive schizophrenia.
DISCUSSION
Table 3. Multivariate Analysis of Variances (MANOVA) for TPH1 A218C in the Aggressive and the Non-Aggressive 
Schizophrenic Patients 
Fd f p
Genotype* 0.76 12 / 226 0.690
Group
� 3.02 6 / 112 0.009
Gender
� 1.78 6 / 112 0.110
Genotype ×Group 0.75 12 / 226 0.699
Genotype ×Gender  0.88 12 / 226 0.568
Group ×Gender 1.99 6 / 112 0.074
Genotype ×Group ×Gender 0.84 12 / 226 0.614
General Linear Model Multivariate Statistics, Pillai-Spur, variables; State-Trait Anger Expression Inventory, factors; genotype, group, gender.
*AA (n = 31) / AC (n = 68) / CC (n = 30).
�Aggressive patients (n = 45) / Non-aggressive patients (n = 84).
�Males (n = 71) / Females (n = 58).
Table 4. Mean Scores for Subscales of the State and Traits Anger Expression Inventory (STAXI) as a Function of TPH 
Genotype in Schizophrenic Patients
Aggressive patients (n = 45) Non-aggressive patients (n = 84)
Genotypic distribution  Analysis Genotypic distribution Analysis
AA AC CC Fp AA AC CC Fp
(n = 10) (n = 24) (n = 11) (df = 2 / 41) (n = 21) (n = 44) (n = 19)  (df = 2 / 80)
State anger 16.0 (6.8) 15.6 (6.5) 16.4 (9.0) 0.03 0.970 13.0 (3.8) 13.4 (4.6) 14.6 (6.2) 0.60 0.554
Trait anger  18.8 (5.6) 20.0 (5.2) 19.1 (6.5) 0.23 0.796 14.7 (3.7) 16.4 (4.6) 17.4 (5.4) 1.80 0.172
Angry reaction 9.4 (3.2) 10.3 (3.3) 9.4 (3.4) 0.43 0.652 7.2 (2.2) 8.7 (2.8) 9.3 (3.3) 2.79 0.067
Angry temperament 9.4 (2.9) 9.7 (3.4) 9.7 (3.6) 0.03 0.974 7.5 (2.2) 7.7 (2.2) 8.2 (2.7) 0.47 0.626
Anger-in 15.5 (5.6) 17.4 (4.7) 14.7 (3.9) 1.59 0.217 14.5 (4.7) 14.8 (3.7) 14.2 (4.4) 0.13 0.875
Anger-out  14.6 (4.6) 15.9 (5.4) 14.7 (4.3) 0.50 0.609 11.2 (3.2) 12.6 (3.7) 13.4 (4.3) 0.98 0.145
Anger control 18.8 (6.3) 21.0 (5.4) 19.6 (4.5) 0.69 0.509 21.2 (5.7) 21.5 (4.8) 23.2 (7.5) 0.70 0.500
Values were mean (SD).
Analysis by univariate ANOVA for the effect of genotype on subscales of STAXI with gender as a covariate.It is interesting to note that our findings are incongruent
with those of a previous study in a Caucasian sample.
11 One
explanation for the discrepancy between our findings and
others may be the small sample sizes of aggressive patients
in both studies: 61 and 42, respectively, coupled with the
fact that the previous positive finding was found in the
sample of 34 male patients. Since it is beyond the means of
most investigators to gather an adequate sample size of
aggressive schizophrenic patients, meta-analyses of well-
prepared small studies should be conducted in the future. 
In this study, the TPH1 genotype had no effect on anger-
related traits in either the aggressive or non-aggressive
schizophrenic patients. In our previous study, aggressive
behavior was more frequent in schizophrenic patients who
were prone to becoming angry.
20 Based on our findings, it
is suspected that other serotonin-related genes, such as
serotonin transporter-related gene,
21 or other TPH gene,
TPH2, which is considered to control serotonin synthesis
in the brain,
22 may play a role in aggressive behavior via
anger-related traits in schizophrenic patients. On the other
hand, as the A218C single nucleotide polymorphism is not
considered to be the sole determinant of the functionality
of the TPH1 gene,
10,23 an analysis of the effect of each
haplotype on the expression of the TPH1 gene is also
required, in order to clarify the involvement of the TPH
gene in aggressive schizophrenia. 
The major strength of the current study is its use of
rigorous criteria to define the phenotype. Thus, although
the recruitment period was twice long as initially planned
because aggressive patients who met the criteria were rare,
the relatively homogenous phenotype of the patients adds
strength to the findings in this study. This study has a few
limitations which need to be taken into consideration,
however. The first limitation is the relatively small sample
size, as already pointed out above. Small sample sizes can
lead to both type 1 and type 2 errors. The power of our
sample was 53% between aggressive patients and healthy
controls, and 42% between aggressive patients and non-
aggressive patients, to detect an allele frequency difference
of 10% at alpha = 0.05 (two-tailed). The second major
limitation is that a self-rating instrument was used to
measure anger-related traits. However, we did not think
that this led to biased results, because the STAXI has
demonstrated high reliability in schizophrenic patients in
other studies.
15 A third limitation is that the severity of
illness could have affected the genotype findings. However,
it seems unlikely to be a confounding factor, as there was
no association between the PANSS score and TPH geno-
type in our subsidiary analysis. A fourth is that ages of
patients with schizophrenia and control subjects were not
matched. 
In conclusion, we could not find any association between
the genetic variations of TPH1 A218C and aggression in
Korean schizophrenia population in the present study.
Despite the present findings, there is no doubt that genetic
variants remain an important factor in aggressive behavior.
Further studies are needed to identify the susceptibility
gene in patients with schizophrenia and other clinical or
non-clinical samples using well-characterized aggression
phenotypes. 
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